CreativeOne Wealth LLC Buys 76 Shares of IQVIA Holdings Inc. (NYSE:IQV)

CreativeOne Wealth LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,227 shares of the medical research company’s stock after acquiring an additional 76 shares during the period. CreativeOne Wealth LLC’s holdings in IQVIA were worth $747,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Quest Partners LLC bought a new stake in IQVIA during the fourth quarter valued at $182,000. Philadelphia Trust Co. lifted its stake in IQVIA by 0.4% during the fourth quarter. Philadelphia Trust Co. now owns 88,520 shares of the medical research company’s stock worth $20,482,000 after purchasing an additional 330 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in IQVIA by 26.2% during the fourth quarter. Coldstream Capital Management Inc. now owns 3,813 shares of the medical research company’s stock worth $882,000 after purchasing an additional 792 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its stake in IQVIA by 5.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 1,667 shares of the medical research company’s stock worth $386,000 after purchasing an additional 90 shares during the last quarter. Finally, Motco lifted its stake in IQVIA by 0.9% during the fourth quarter. Motco now owns 36,324 shares of the medical research company’s stock worth $8,405,000 after purchasing an additional 320 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 1.5 %

NYSE:IQV opened at $226.00 on Thursday. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The firm has a market capitalization of $41.18 billion, a price-to-earnings ratio of 30.87, a price-to-earnings-growth ratio of 2.09 and a beta of 1.52. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The business has a fifty day moving average price of $238.14 and a 200-day moving average price of $228.32.

Insiders Place Their Bets

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on IQV shares. SVB Leerink assumed coverage on IQVIA in a research note on Monday, February 26th. They set an “outperform” rating and a $290.00 price target for the company. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Robert W. Baird reduced their price target on IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a report on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Finally, UBS Group boosted their price target on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $257.57.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.